Kestra Medical CCO sells shares for tax withholding

Kestra Medical Technologies’ Chief Commercial Officer Alfred J. Ford Jr. reported selling a total of 27,632 Common Shares of KMTS across three transactions on July 30, July 31, and August 3, 2026.

Rhea-AI Filing Summary

Kestra Medical Technologies’ Chief Commercial Officer Alfred J. Ford Jr. reported selling a total of 27,632 Common Shares of KMTS across three transactions on July 30, July 31, and August 3, 2026. These sales, reported as open‑market or private transactions at weighted‑average prices between $22.17 and $24.28 per share, are described as nondiscretionary “sell‑to‑cover” trades made to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units.

Insider Trade Summary

Net Seller: 27,632 shares

Net Sell 3 txns

Insider Ford Alfred J Jr

Role Chief Commercial Officer

Sold 27,632 shs ($643K)

Type	Security	Shares	Price	Value
Sale	Common Shares F1, F4	13,015	$23.9046	$311K
Sale	Common Shares F1, F3	8,681	$22.6108	$196K
Sale	Common Shares F1, F2	5,936	$22.7629	$135K

Holdings After Transaction: Common Shares — 105,839 shares (Direct)

Footnotes (4)

1. F1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2696 to $23.2000. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
3. F3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1700 to $22.9000. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
4. F4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6600 to $24.2800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Key Figures

Total shares sold: 27,632 Common Shares Shares sold 2026-07-30: 5,936 Common Shares Shares sold 2026-07-31: 8,681 Common Shares +2 more

5 metrics

Total shares sold 27,632 Common Shares Aggregate non-derivative sales reported across July 30–August 3, 2026

Shares sold 2026-07-30 5,936 Common Shares Weighted-average price $22.7629; sale price range $22.2696–$23.2000

Shares sold 2026-07-31 8,681 Common Shares Weighted-average price $22.6108; sale price range $22.1700–$22.9000

Shares sold 2026-08-03 13,015 Common Shares Weighted-average price $23.9046; sale price range $23.6600–$24.2800

Transaction purpose Sell-to-cover tax withholding Footnote states sales were required to satisfy tax withholding for RSU vesting and settlement

Key Terms

sell to cover transactions, tax withholding obligations, restricted stock units, weighted average price

4 terms

sell to cover transactions financial

"represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions"

tax withholding obligations financial

"sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement"

restricted stock units financial

"tax withholding obligations in connection with the vesting and settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price in Column 4 is a weighted average price. The prices at which the reported securities were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Kestra Medical Technologies (KMTS) report in this Form 4?

Kestra Medical Technologies reported that Chief Commercial Officer Alfred J. Ford Jr. sold 27,632 Common Shares of KMTS over three days. The transactions are characterized as nondiscretionary “sell‑to‑cover” trades to satisfy tax withholding obligations from restricted stock unit vesting and settlement.

How many Kestra Medical (KMTS) shares did the CCO sell on each reported date?

Alfred J. Ford Jr. sold 5,936 shares on July 30, 8,681 shares on July 31, and 13,015 shares on August 3, 2026. All transactions involved KMTS Common Shares held directly and are tied to tax‑related sell‑to‑cover activity for restricted stock units.

At what prices were the Kestra Medical (KMTS) shares sold in these Form 4 transactions?

Each trade used a weighted‑average price. On July 30, the average was $22.7629 with a range of $22.2696–$23.2000. On July 31, the average was $22.6108 with a range of $22.1700–$22.9000. On August 3, the average was $23.9046 with a range of $23.6600–$24.2800.

Were the KMTS insider share sales by the CCO discretionary or related to taxes?

A key footnote explains that the sales represent nondiscretionary “sell‑to‑cover” transactions required to satisfy tax withholding obligations. They are linked to the vesting and settlement of restricted stock units, indicating the purpose was to cover taxes rather than initiate discretionary selling.

Were the Kestra Medical (KMTS) insider transactions under a Rule 10b5-1 trading plan?

The document‑level Rule 10b5‑1 checkbox is not marked as an affirmatively adopted trading plan. Instead, footnote language characterizes the reported sales as sell‑to‑cover transactions for tax withholding tied to restricted stock units, rather than trades executed under a Rule 10b5‑1 plan.

Does the Form 4 show how many KMTS shares the CCO holds after these sales?

For each reported sale, the post‑transaction holdings field is not populated, so the filing does not state Alfred J. Ford Jr.’s remaining KMTS Common Share balance. The disclosure focuses on the 27,632 shares sold and the tax‑related purpose of those transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 07:33 PM Accepted by SEC EDGAR 08/03/2026 - 07:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ford Alfred J Jr

(Last) (First) (Middle)

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WASHINGTON 98033

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/30/2026		S(1)		5,936	D	$22.7629(2)	127,535	D
Common Shares	07/31/2026		S(1)		8,681	D	$22.6108(3)	118,854	D
Common Shares	08/03/2026		S(1)		13,015	D	$23.9046(4)	105,839	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2696 to $23.2000. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

3. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.1700 to $22.9000. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

4. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.6600 to $24.2800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

	/s/ Traci S. Umberger as attorney-in-fact for Alfred J. Ford Jr.	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)